WVU research shows how much pharmaceutical companies are capitalizing on rare drug incentives
So-called “orphan” drugs that treat diseases affecting fewer than 200,000 Americans earn pharmaceutical companies as much money as mainstream medications, according to research from Sean Tu, a West Virginia University College of Law professor.